KEI and UACT comments on the prospective grant of exclusive licenses to Sinotau and MTTI

On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading

Joint comments on the NIH license to patents on CAR therapies to CJ Healthcare

Joint Comments Regarding “Prospective Grant of an Exclusive Patent License: Development and Commercialization of CD19/CD22 Chimeric Antigen Receptor (CAR) Therapies for the Treatment of B-Cell Malignancies[,]” 85 FR 328 On January 21, 2020 five groups and two individuals filed comments… Continue Reading

KEI Comments Regarding NIH Exclusive License on Gene Therapy to Treat Ocular Disease

On Friday January 10, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Gene Therapy for Ocular Disease” to OcQuila Therapeutics, Ltd. (84 FR 65169). The… Continue Reading

KEI Requests the NIH to Investigate Failure to Disclose Federal Funding in Opdivo and Keytruda Patents

On December 20, 2019, Knowledge Ecology International (KEI) filed a request to the National Institutes of Health (NIH) that it investigate an apparent failure to disclose federal funding in patents associated with cancer immunotherapies Opdivo and Keytruda. A court case… Continue Reading

KEI, UACT, Public Citizen, SSW, LWC Health Appeal NIH Grant of Exclusive License on Gene Therapy for Cancer to Intima Biosciences

On October 26, 2019, Knowledge Ecology International (KEI), Union for Affordable Cancer Treatment (UACT), Public Citizen, Social Security Works (SSW), LWC Health, Ruth Lopert, Manon Ress, and Terry Love filed an administrative appeal with the National Institutes of Health (NIH).… Continue Reading

KEI and UACT Comments Regarding NIH Exclusive License on GPC3-Expressing Cancer Treatment

On Tuesday November 12, 2019, KEI and the Union for Affordable Cancer Treatment (UACT) filed comments on the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: The Development of an Anti-GPC3 Radionuclide Immunoconjugate for the Treatment… Continue Reading

Trilateral symposium: WTO Director General Roberto Azevêdo highlights the opportunities and challenges faced in providing access to CAR T

On Thursday, 31 October 2019, the World Trade Organization (WTO) hosted the eighth trilateral symposium jointly convened by the World Health Organization (WHO) and the World Intellectual Property Organization (WIPO). The theme of this year’s symposium was ” “Cutting-Edge Health… Continue Reading

KEI Comments to the NIH on Exclusive License to Opsis Therapeutics for Retinal Cell Therapies

On October 18, 2019, Knowledge Ecology International (KEI) submitted comments to the Federal Register Notice for the “Prospective Grant of an Exclusive Patent License: Compositions, Devices and Processes for Production and Delivery of Cell Grafts of Manufactured Retinal Pigment Epithelium… Continue Reading

KEI and UACT Comments to NIH on License to T-Cell Therapy for Cancer to Ziopharm Oncology

On Friday October 18, 2019, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) submitted comments on the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer” (84 FR 52890)by the National… Continue Reading

KEI and UACT Comments to NIH on License in AAV Vectors to Generation Bio and Spark Therapeutics

On Friday October 11, 2019, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) submitted comments to the Federal Register notice (84 FR 51171) for the “Prospective Grant of Exclusive Patent License: Capsid-Free AAV Vectors, Compositions, and Methods… Continue Reading